Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Scotland Greenlights More Rare Disease Treatments

Executive Summary

Scotland’s health technology appraisal body has OKd Alynlam’s Onpattro, AstraZeneca's Imfinzi and Takeda’s Alunbrig for use on the Scottish National Health Service.

You may also be interested in...



NICE Says Yes To Akcea’s Tegsedi After ‘Improved’ Commercial Offer

NICE has given the green light to Akcea Therapeutics’ ultra-rare disease treatment Tegsedi (inotersen) after the company offered a better “commercial arrangement.”

Drug Pricing ‘Not Appropriate Topic’ For WTO TRIPS Council

The World Trade Organization is not the place to discuss pharmaceutical pricing, and strong intellectual property rights do not threaten access to medicines, according to EU and US delegations to the WTO.

Brazilian Regulator Approves New Advanced Therapy Regulations

Brazil’s medicines regulator, ANVISA, finally has a new set of rules for the evaluation and marketing authorization of advanced therapy medicines.

Topics

UsernamePublicRestriction

Register

PS125466

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel